Verrica Pharmaceuticals Inc VRCA.OQ VRCA.O is expected to show a rise in quarterly revenue when it reports results for the period ending December 31 2024
The West Chester Pennsylvania-based company is expected to report a 202.0% increase in revenue to $6.004 million from $1.99 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Verrica Pharmaceuticals Inc is for a loss of 34 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 8.2% in the last three months.
Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $8.50, above its last closing price of $0.80.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.39 | -0.37 | -0.49 | Missed | -33.5 |
Jun. 30 2024 | -0.43 | -0.42 | -0.37 | Beat | 12.9 |
Mar. 31 2024 | -0.46 | -0.40 | -0.44 | Missed | -10.9 |
Jan. 1 0001 | -0.53 | -0.53 | -0.53 | Met | -0.4 |
Sep. 30 2023 | -0.35 | -0.36 | -0.54 | Missed | -49.5 |
Jun. 30 2023 | -0.22 | -0.21 | -0.24 | Missed | -14.2 |
Jan. 1 0001 | -0.18 | -0.19 | -0.15 | Beat | 21.1 |
Jan. 1 0001 | -0.19 | -0.19 | -0.14 | Beat | 27.3 |
This summary was machine generated November 6 at 14:20 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。